Literature DB >> 21309040

Databases in the area of pharmacogenetics.

Sarah C Sim1, Russ B Altman, Magnus Ingelman-Sundberg.   

Abstract

In the area of pharmacogenetics and personalized health care it is obvious that databases, providing important information of the occurrence and consequences of variant genes encoding drug metabolizing enzymes, drug transporters, drug targets, and other proteins of importance for drug response or toxicity, are of critical value for scientists, physicians, and industry. The primary outcome of the pharmacogenomic field is the identification of biomarkers that can predict drug toxicity and drug response, thereby individualizing and improving drug treatment of patients. The drug in question and the polymorphic gene exerting the impact are the main issues to be searched for in the databases. Here, we review the databases that provide useful information in this respect, of benefit for the development of the pharmacogenomic field.
© 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21309040      PMCID: PMC3352027          DOI: 10.1002/humu.21454

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  41 in total

Review 1.  Inheritance and drug response.

Authors:  Richard Weinshilboum
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

Review 2.  Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future.

Authors:  Magnus Ingelman-Sundberg
Journal:  Trends Pharmacol Sci       Date:  2004-04       Impact factor: 14.819

Review 3.  Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.

Authors:  J Kirchheiner; K Nickchen; M Bauer; M-L Wong; J Licinio; I Roots; J Brockmöller
Journal:  Mol Psychiatry       Date:  2004-05       Impact factor: 15.992

Review 4.  Pharmacogenomics and individualized drug therapy.

Authors:  Michel Eichelbaum; Magnus Ingelman-Sundberg; William E Evans
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

5.  The human cytochrome P450 Allele Nomenclature Committee Web site: submission criteria, procedures, and objectives.

Authors:  Sarah C Sim; Magnus Ingelman-Sundberg
Journal:  Methods Mol Biol       Date:  2006

Review 6.  Drug-induced liver injury: past, present and future.

Authors:  Ann K Daly
Journal:  Pharmacogenomics       Date:  2010-05       Impact factor: 2.533

Review 7.  Arylamine N-acetyltransferases: structural and functional implications of polymorphisms.

Authors:  Edith Sim; Nathan Lack; Chan-Ju Wang; Hilary Long; Isaac Westwood; Elizabeth Fullam; Akane Kawamura
Journal:  Toxicology       Date:  2008-09-12       Impact factor: 4.221

8.  Generating genome-scale candidate gene lists for pharmacogenomics.

Authors:  N T Hansen; S Brunak; R B Altman
Journal:  Clin Pharmacol Ther       Date:  2009-04-15       Impact factor: 6.875

9.  The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects.

Authors:  Sarah C Sim; Magnus Ingelman-Sundberg
Journal:  Hum Genomics       Date:  2010-04       Impact factor: 4.639

10.  Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes.

Authors:  Emma C Davies; Christopher F Green; Stephen Taylor; Paula R Williamson; David R Mottram; Munir Pirmohamed
Journal:  PLoS One       Date:  2009-02-11       Impact factor: 3.240

View more
  15 in total

1.  Identifying aberrant pathways through integrated analysis of knowledge in pharmacogenomics.

Authors:  Robert Hoehndorf; Michel Dumontier; Georgios V Gkoutos
Journal:  Bioinformatics       Date:  2012-06-17       Impact factor: 6.937

Review 2.  Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer.

Authors:  Shanbeh Zienolddiny; Vidar Skaug
Journal:  Lung Cancer (Auckl)       Date:  2011-12-29

3.  Polypharmacy: a healthcare conundrum with a pharmacogenetic solution.

Authors:  Cierra N Sharp; Mark W Linder; Roland Valdes
Journal:  Crit Rev Clin Lab Sci       Date:  2019-11-02       Impact factor: 6.250

4.  PharmGKB: the Pharmacogenomics Knowledge Base.

Authors:  Caroline F Thorn; Teri E Klein; Russ B Altman
Journal:  Methods Mol Biol       Date:  2013

5.  Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease.

Authors:  Edward D Esplin; Ling Oei; Michael P Snyder
Journal:  Pharmacogenomics       Date:  2014-11       Impact factor: 2.533

Review 6.  Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer.

Authors:  Tim N Beck; Adaeze J Chikwem; Nehal R Solanki; Erica A Golemis
Journal:  Physiol Genomics       Date:  2014-08-05       Impact factor: 3.107

7.  Genetic polymorphisms of pharmacogenomic VIP variants in the Mongol of Northwestern China.

Authors:  Tianbo Jin; Xugang Shi; Li Wang; Huijuan Wang; Tian Feng; Longli Kang
Journal:  BMC Genet       Date:  2016-05-28       Impact factor: 2.797

Review 8.  Pharmacogenomics of chemotherapeutic susceptibility and toxicity.

Authors:  Erika L Moen; Lucy A Godley; Wei Zhang; M Eileen Dolan
Journal:  Genome Med       Date:  2012-11-30       Impact factor: 11.117

9.  Deciphering next-generation pharmacogenomics: an information technology perspective.

Authors:  George Potamias; Kleanthi Lakiotaki; Theodora Katsila; Ming Ta Michael Lee; Stavros Topouzis; David N Cooper; George P Patrinos
Journal:  Open Biol       Date:  2014-07       Impact factor: 6.411

10.  Efficacy of computational predictions of the functional effect of idiosyncratic pharmacogenetic variants.

Authors:  Hannah McConnell; T Daniel Andrews; Matt A Field
Journal:  PeerJ       Date:  2021-07-15       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.